NEW YORK (GenomeWeb News) — Canadian biomarker company Miraculins has withdrawn its offer to acquire diagnostics developer IBEX technologies.
 
In mid-November Winnipeg-based Miraculins made an unsolicited offer to acquire IBEX through a stock deal that would exchange one common Miraculins share for five shares in IBEX.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.